IN8bio, Inc. Common Stock (INAB)

IN8bio, Inc. (INAB) is a clinical-stage biotechnology company focused on developing innovative cell therapies for the treatment of resistant and hard-to-treat cancers. The company leverages its proprietary gamma delta T cell platform to engineer and enhance immune responses against tumors, aiming to improve patient outcomes through its advanced immunotherapy approaches.

🚫 IN8bio, Inc. Common Stock does not pay dividends

Company News

IN8bio Recognizes Achievement of 4-Years in Remission for Patient Treated with INB-200 in Glioblastoma Trial
GlobeNewswire Inc. • N/A • June 9, 2025

IN8bio's gamma-delta T cell therapy INB-200 has demonstrated a significant clinical milestone, with a patient with a grade 4, IDH-mutant glioma remaining in remission and progression-free for 4 years after treatment. This outcome highlights the potential of INB-200 in treating this aggressive and deadly cancer.

Why PriceSmart Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Benzinga • Avi Kapoor • April 10, 2024

Shares of PriceSmart, Inc. (NASDAQ: PSMT) rose sharply in today’s pre-market trading as the company posted better-than-expected earnings for its second quarter. The company reported quarterly earnings of $1.31 per share, beating market estimates of $1.25 per share. PriceSmart’s quarterly sales came in at $1.29 billion versus expectations of $1.28 billion, according to data from Benzinga Pro. PriceSmart shares surged 4.6% to $86.90 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Marin Software Incorporated (NASDAQ: MRIN) shares rose 76.1% to $0.5054 in pre-market trading after the company announced upgrades to its Microsoft Corp (NASDAQ: MSFT) advertising integration. iCoreConnect Inc. (NASDAQ: ICCT) shares rose 46.4% to $1.64 in pre-market trading. iCoreConnect, last month, closed $2,375,000 convertible note financing. Nano Labs Ltd (NASDAQ: NA) gained 35.1% to $2.00 in pre-market trading. Nano Labs recently filed annual report on Form 20-F for fiscal year 2023. IN8bio, Inc. (NASDAQ: INAB) shares gained 20.2% to $1.31 in pre-market trading after the company announced new preclinical data from its non-signaling gamma-delta ...

Wall Street Breakfast: The Week Ahead
Seeking Alpha • Wall Street Breakfast • December 10, 2023

Get the latest financial updates and insights with Wall Street Breakfast's daily podcast available on Seeking Alpha, iTunes, and Spotify.

Here's Why IN8bio, Inc. (INAB) Could be Great Choice for a Bottom Fisher
Zacks Investment Research • Zacks Equity Research • November 23, 2023

IN8bio, Inc. (INAB) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Best Penny Stocks To Buy Today? 4 To Watch Under $5
PennyStocks • J. Samuel • May 4, 2023

Penny stocks under $5 to watch this week. The post Best Penny Stocks To Buy Today? 4 To Watch Under $5 appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.